Email this article ALTERNATIVE WAYS TO ACTIVATE THE CHEMOTAXIS OF ACUTE MYELOID LEUKEMIA CELLS
- Authors: Filina A.B.1,2, Svitich O.A.1,2, Golenkov A.K.3, Klinushkina E.F.3, Zverev V.V.1,2
-
Affiliations:
- Mechnikov Research Institute of Vaccines and Sera
- First Moscow I. M. Sechenov State Medical University
- SBHI of MA MRRCI n. a. M. F. Vladimirskiy
- Issue: Vol 22, No 2-1 (2019)
- Pages: 596-598
- Section: ORIGINAL ARTICLES
- Submitted: 19.05.2020
- Accepted: 19.05.2020
- Published: 15.04.2019
- URL: https://rusimmun.ru/jour/article/view/228
- DOI: https://doi.org/10.31857/S102872210006986-9
- ID: 228
Cite item
Full Text
Abstract
One of the main factors of innate immunity involved in tumor progression and metastasis are TLRs, ligands of TLRs, chemokines and their receptors. The relationship between the above factors and the oncological process was studied not revrntly, but the last decade has been actively studied by scientists from all over the world. Despite the great interest in this issue, a more detailed study so far concerns only a few chemokines, such as CXCL12, CCL8 and their receptors, as well as TLRs and their ligands. Thus, in our work, we wanted to explore possible options for mediated chemotaxis of leukemia cells, as well as the eff ect of heterologous receptor activation on each other.
Keywords
About the authors
A. B. Filina
Mechnikov Research Institute of Vaccines and Sera;First Moscow I. M. Sechenov State Medical University
Author for correspondence.
Email: byzonka@yandex.ru
Junior Researcher, Laboratory of Molecular Immunology,
Moscow
Russian FederationO. A. Svitich
Mechnikov Research Institute of Vaccines and Sera;First Moscow I. M. Sechenov State Medical University
Email: fake@neicon.ru
Cor. Memb. RAS, Ph D., director of the Mechnikov Research Institute of Vaccines and Sera,
Moscow
Russian FederationA. K. Golenkov
SBHI of MA MRRCI n. a. M. F. Vladimirskiy
Email: fake@neicon.ru
PhD, professor, hematologist, head of the clinic of clinical hematology and immunotherapy,
Moscow
Russian FederationE. F. Klinushkina
SBHI of MA MRRCI n. a. M. F. Vladimirskiy
Email: fake@neicon.ru
hematologist, head of the department of clinical hematology and immunotherapy,
Moscow
Russian FederationV. V. Zverev
Mechnikov Research Institute of Vaccines and Sera;First Moscow I. M. Sechenov State Medical University
Email: fake@neicon.ru
PhD, Academician of RAS, DSc, Scientifi c Director of the Research,
Moscow
Russian FederationReferences
- Mills S. C., Goh P. H., Kudatsih J., Ncube S., Gurung R., Maxwell W., & Mueller A. (2016). Cell migration towards CXCL12 in leukemic cells compared to breast cancer cells. Cellular Signalling, 28(4), 316–324
- Pradere J. P., Dapito D. H., & Schwabe R. F. (2013). The Yin and Yang of Toll-like receptors in cancer. Oncogene, 33(27), 3485–95.
- Webb R. N., Cruse J. M., & Lewis R. E. (2007). Differential cytokine and Toll-like receptor expression in leukemia. Experimental and Molecular Pathology, 83(3), 464–470.
Supplementary files
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).